DEFA14A: Dar Bioscience Adjourns Annual Stockholders Meeting Due to Lack of Quorum, Reschedules for July 9

Dar Bioscience, Inc. announced the adjournment of its 2025 annual meeting of stockholders due to a lack of the required quorum, with the meeting now set to reconvene virtually on Wednesday, July 9, 2025.

Summary

• Dar Bioscience, Inc. (NASDAQ: DARE) convened its 2025 annual meeting of stockholders on June 12, 2025, but immediately adjourned it without conducting any business.
• The adjournment was necessary due to a lack of the required quorum, as fewer than a majority of shares entitled to vote were present, either in person or by proxy.
• The Annual Meeting will reconvene virtually on Wednesday, July 9, 2025, at 9:00 a.m. Pacific Time.
• Stockholders who have already submitted a proxy or voted do not need to vote again, as previous submissions remain valid.
• The record date for determining eligible voters remains April 17, 2025.
• Stockholders are encouraged to vote online or by telephone by 11:59 p.m. Eastern Time on July 8, 2025.
• The company's definitive proxy statement was filed with the SEC on April 24, 2025, and no changes have been made to the proposals to be voted on.
• Dar Bioscience is a biopharmaceutical company focused on women's health, aiming to bring innovative, evidence-based solutions to market.
• Their portfolio includes the FDA-approved XACIATO (clindamycin phosphate) vaginal gel 2% for bacterial vaginosis, licensed to Organon.
• Clinical development candidates include Ovaprene (hormone-free contraceptive, licensed to Bayer), Sildenafil Cream, 3.6% (for female sexual arousal disorder), and DARE-HRT1 (menopausal hormone therapy intravaginal ring).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the adjournment of the annual meeting due to lack of quorum is a minor negative procedural event, the underlying business description of Dar Bioscience, its mission in women's health, existing FDA-approved product, and pipeline candidates are positive. The document primarily focuses on a procedural update rather than financial performance or strategic shifts.

Positives

• Dar Bioscience is dedicated to addressing unmet needs in women's health, a significant and often underserved market.
• The company has an FDA-approved product, XACIATO, which is under a global license agreement with Organon, indicating successful product development and commercialization potential.
• Their pipeline includes several potential first-in-category candidates in clinical development, such as Ovaprene, Sildenafil Cream, 3.6%, and DARE-HRT1, suggesting future growth opportunities.
• The company leverages existing clinical proof of concept or safety data for active ingredients, which can potentially accelerate development timelines and reduce costs.
• Dar Bioscience leadership has received industry recognition, including being named on the Medicine Makers Power List and Endpoints News Women in Biopharma, and the CEO being honored by Fierce Pharma.

Negatives

• The 2025 annual meeting of stockholders was adjourned due to a lack of the required quorum, indicating insufficient shareholder engagement or participation.
• The need to solicit additional proxies suggests a challenge in securing sufficient votes for the meeting's agenda.

Risks

• Failure to achieve quorum at the reconvened annual meeting could further delay corporate governance actions and potentially impact investor confidence.
• Low shareholder engagement, as evidenced by the lack of quorum, could signal broader concerns about investor interest or communication effectiveness.
• Reliance on securing additional proxies to meet quorum requirements highlights a potential vulnerability in shareholder relations.

Future Outlook

Dar Bioscience aims to bring innovative, evidence-based solutions to market as soon as practicable, addressing unmet needs in women's health. The company plans to continue advancing its portfolio of product candidates, including Ovaprene, Sildenafil Cream, 3.6%, and DARE-HRT1, leveraging existing clinical data to optimize access for women.

Management Comments

• Dar Bioscience is 'driven by a mission to challenge the status quo, making womens health a priority.'
• The company 'believes that innovation does not have to start from scratch.'
• Their goal is 'to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in womens health and enhance outcomes and convenience.'
• Dar seeks to bring solutions to market 'in ways designed to optimize access for women in a fiscally responsible manner.'

Industry Context

This announcement highlights the procedural challenges that can arise in corporate governance, even for biopharmaceutical companies focused on critical health areas like women's health. While the core business of Dar Bioscience is innovation in a high-demand sector, the adjournment due to lack of quorum underscores the importance of shareholder engagement and effective proxy solicitation, a common challenge across various industries, particularly for smaller or growth-stage companies.

Stakeholder Impact

• Shareholders: Required to take action to vote if they have not already, to ensure quorum is met at the reconvened meeting. Their ability to vote on proposals is delayed.
• Management/Board: Must actively solicit additional proxies to ensure the reconvened meeting achieves quorum, potentially diverting resources.
• Company Operations: Delays in formalizing any decisions or appointments that were on the agenda for the annual meeting.

Next Steps

• Stockholders are encouraged to vote online or by telephone by July 8, 2025, to ensure their votes are counted for the reconvened meeting.
• The 2025 annual meeting of stockholders will reconvene virtually on July 9, 2025, at 9:00 a.m. Pacific Time.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Women's Health, SEC Filing, Proxy Statement, Annual Meeting, Corporate Governance, Quorum, XACIATO, Ovaprene, Sildenafil Cream, DARE-HRT1, Clinical Development, FDA Approved